AstraZeneca announced Airsupra is now commercially available in the U.S. by prescription. Airsupra received FDA approval in January 2023 for the as-needed treatment or prevention of symptoms of asthma and to help prevent sudden severe breathing problems in people aged 18 years and older.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AZN:
- AstraZeneca says Imfinzi combo improved survival in carcinoma patients
- AstraZeneca reports Voydeya granted regulatory approval in Japan
- AstraZeneca price target raised to 13,400 GBp from 12,900 GBp at Morgan Stanley
- AstraZeneca downgraded to Sell from Buy at UBS
- AIM ImmunoTech announces open enrollment for Phase 1b/2 study of Ampligen